Passage Bio will develop therapies for diseases affecting the central nervous system based on research by James Wilson at Penn, after raising almost $116m in a series A round.

Passage Bio, a US-based company developing treatments for neurological diseases based on research at University of Pennsylvania, has received $115.5m in a series A round that included Lilly Asia Ventures, an investment vehicle for pharmaceutical firm Eli Lilly.
The round was led by OrbiMed and included fellow healthcare investment firm Vivo Capital as well as venture capital firms Frazier Healthcare Partners, Versant Ventures and New Leaf Venture Partners.
Passage Bio is developing five drug candidates that are intended…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?